Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Magazines
Fall Home Improvements
Women
Home & Realty
Outdoor Guide
Premier Home Style Tour 2024
Spring Home & Garden Show
Spring on the Road
Spring Wellness
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
Parcel Pickup
2024 Readersâ Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Royalty Pharma Plc Cl A
(NQ:
RPRX
)
26.43
+0.03 (+0.11%)
Streaming Delayed Price
Updated: 4:00 PM EST, Nov 22, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Royalty Pharma Plc Cl A
< Previous
1
2
3
4
5
6
7
Next >
$122M Bet On Occidental Petroleum? Check Out These 3 Stocks Insiders Are Buying
June 29, 2023
Although US stocks closed mixed on Wednesday, there were a few notable insider trades.
Via
Benzinga
Stocks That Hit 52-Week Lows On Friday
June 16, 2023
Friday's session saw 32 companies set new 52-week lows.
Via
Benzinga
Stocks That Hit 52-Week Lows On Thursday
June 15, 2023
On Thursday, 64 companies achieved new lows for the year.
Via
Benzinga
$10M Bet On GameStop? Check Out These 3 Stocks Insiders Are Buying
June 14, 2023
Although US stocks closed higher on Tuesday, there were a few notable insider trades.
Via
Benzinga
Earnings Outlook For Royalty Pharma
May 08, 2023
Via
Benzinga
Royalty Pharma to Present at the Goldman Sachs 44th Annual Global Healthcare Conference
June 07, 2023
From
Royalty Pharma plc
Via
GlobeNewswire
The Biotech Buying Bonanza: Why The FTC's Amgen Battle Won't Chill The Spree
June 02, 2023
Big Pharma is facing a patent cliff that could siphon off billions in revenue.
Via
Investor's Business Daily
Stocks That Hit 52-Week Lows On Wednesday
May 24, 2023
On Wednesday, 129 stocks made new 52-week lows.
Via
Benzinga
Preview: Royalty Pharma's Earnings
February 14, 2023
Via
Benzinga
Ominous Death Cross Forms On Royalty Pharma's Chart
January 10, 2023
Via
Benzinga
$12.5M Bet On Energy Transfer? Check Out These 4 Stocks Insiders Are Buying
May 18, 2023
Although US stocks closed higher on Wednesday, there were a few notable insider trades.
Via
Benzinga
Royalty Pharma Reaffirms FY23 Guidance Post Mixed Q1 Performance
May 09, 2023
Via
Benzinga
Royalty Pharma Reports First Quarter 2023 Results
May 09, 2023
From
Royalty Pharma plc
Via
GlobeNewswire
Royalty Pharma To Present At The BofA Securities 2023 Health Care Conference
May 03, 2023
From
Royalty Pharma plc
Via
GlobeNewswire
Royalty Pharma Declares Second Quarter 2023 Dividend
April 17, 2023
From
Royalty Pharma plc
Via
GlobeNewswire
Royalty Pharma to Announce First Quarter 2023 Financial Results on May 9, 2023
April 13, 2023
From
Royalty Pharma plc
Via
GlobeNewswire
Royalty Pharma Announces $1.0 Billion Share Repurchase Program
March 27, 2023
From
Royalty Pharma plc
Via
GlobeNewswire
Royalty Pharma and PureTech Health Enter Into KarXT Royalty Agreement for Up to $500 Million
March 23, 2023
From
Royalty Pharma plc
Via
GlobeNewswire
PureTech Health and Royalty Pharma Enter into KarXT Royalty Agreement for up to $500 Million
March 23, 2023
From
PureTech Health plc
Via
Business Wire
Royalty Pharma Raises Full Year 2023 Guidance
March 15, 2023
From
Royalty Pharma plc
Via
GlobeNewswire
Royalty Pharma Appoints Ashwin Pai as Executive Vice President, Investments
March 01, 2023
From
Royalty Pharma plc
Via
GlobeNewswire
Stocks That Hit 52-Week Lows On Tuesday
February 28, 2023
During Tuesday, 79 stocks hit new 52-week lows.
Via
Benzinga
Insiders Selling TransMedics Group And 2 Other Stocks
February 28, 2023
The Nasdaq 100 closed higher by around 0.7% on Monday. Investors, meanwhile, focused on some notable insider trades.
Via
Benzinga
Top 5 Health Care Stocks That May Rocket Higher In Q1 2023
February 27, 2023
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
Via
Benzinga
Royalty Pharma Reports Q4 and Full Year 2022 Results
February 15, 2023
From
Royalty Pharma plc
Via
GlobeNewswire
Royalty Pharma to Present at Upcoming Investor Conferences
February 09, 2023
From
Royalty Pharma plc
Via
GlobeNewswire
February PDUFA Catalysts Biotech Investors Must Know: Sanofi's Bleeding Disorder Drug, Regeneron's Twin Eylea Label Expansions, 3 Delayed Approvals And More
January 31, 2023
The year has started well for biopharma companies on the regulatory front, as most decisions handed out during January were positive. The Food and Drug Administration has already cleared four new...
Via
Benzinga
Five Best And Worst Performing Healthcare Stocks In December 2022
January 22, 2023
Multiple factors are expected to help the healthcare industry overcome inflationary pressures. If you are looking to invest in this sector, then to help you select, here are the five best and worst...
Via
Talk Markets
Royalty Pharma To Announce Fourth Quarter And Full Year 2022 Financial Results On February 15, 2023
January 18, 2023
From
Royalty Pharma plc
Via
GlobeNewswire
Royalty Pharma Highlights Accomplishments and Provides Business Update at 41st Annual J.P. Morgan Healthcare Conference
January 09, 2023
From
Royalty Pharma plc
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.